ADMA Historical Financial Ratios

ADMA Stock

USD 17.70 0.93 4.99%

ADMA Biologics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0694, PTB Ratio of 7.86 or Days Sales Outstanding of 41.63 will help investors to properly organize and evaluate ADMA Biologics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

About ADMA Financial Ratios Analysis

ADMA BiologicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ADMA Biologics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ADMA financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ADMA Biologics history.

ADMA Biologics Financial Ratios Chart

At present, ADMA Biologics' PTB Ratio is projected to drop based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 41.63, whereas Price To Sales Ratio is forecasted to decline to 3.72.

Price To Sales Ratio Days Sales Outstanding Operating Cash Flow Per Share Stock Based Compensation To Revenue Roic Operating Cycle

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing ADMA Biologics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ADMA Biologics sales, a figure that is much harder to manipulate than other ADMA Biologics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Most ratios from ADMA Biologics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' PTB Ratio is projected to drop based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 41.63, whereas Price To Sales Ratio is forecasted to decline to 3.72.

	2023	2024 (projected)
Dividend Yield	0.0781	0.0694
Price To Sales Ratio	3.92	3.72

Dividend Yield Price To Sales Ratio

ADMA Biologics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding
Price To Sales Ratio		0.27	0.0	-0.6	0.21	-0.13	-0.56	-0.84	-0.05	0.0	0.99	-0.56	-0.47	-0.4	-0.56	0.63	-0.71	-0.55	0.04	0.72	-0.29	-0.96	-0.26	-0.16	-0.29	0.94
Dividend Yield	0.27		0.04	0.04	0.06	-0.43	-0.29	-0.16	0.17	0.04	0.28	-0.3	-0.5	-0.05	-0.24	0.17	-0.68	-0.56	0.35	0.34	-0.95	-0.22	-0.75	-0.91	-0.95	0.31
Ptb Ratio	0.0	0.04		-0.03	-0.23	0.19	0.03	-0.04	-0.05	1.0	0.05	0.03	-0.15	0.08	0.02	-0.18	-0.15	-0.16	-0.17	-0.01	-0.06	0.12	-0.05	0.0	-0.05	-0.04
Days Sales Outstanding	-0.6	0.04	-0.03		-0.04	-0.32	0.28	0.64	0.13	-0.03	-0.59	0.27	0.33	-0.09	0.31	-0.01	0.35	0.47	0.29	-0.48	-0.02	0.49	-0.05	-0.15	-0.04	-0.56
Book Value Per Share	0.21	0.06	-0.23	-0.04		0.21	0.23	-0.14	-0.02	-0.23	0.1	0.23	0.38	-0.03	0.2	0.08	-0.21	-0.12	0.06	0.29	-0.1	-0.17	-0.1	-0.07	-0.09	0.41
Free Cash Flow Yield	-0.13	-0.43	0.19	-0.32	0.21		0.74	0.16	0.03	0.19	-0.14	0.74	0.64	0.05	0.7	-0.22	0.26	0.23	-0.28	-0.39	0.41	0.22	0.43	0.41	0.44	-0.13
Operating Cash Flow Per Share	-0.56	-0.29	0.03	0.28	0.23	0.74		0.53	0.07	0.03	-0.56	1.0	0.84	0.18	1.0	-0.34	0.5	0.44	-0.05	-0.79	0.28	0.56	0.29	0.21	0.3	-0.54
Average Payables	-0.84	-0.16	-0.04	0.64	-0.14	0.16	0.53		0.18	-0.04	-0.84	0.53	0.58	0.03	0.53	-0.26	0.72	0.77	0.08	-0.68	0.24	0.8	0.33	0.06	0.25	-0.81
Capex To Depreciation	-0.05	0.17	-0.05	0.13	-0.02	0.03	0.07	0.18		-0.05	-0.01	0.04	0.08	0.32	0.08	-0.23	-0.08	-0.03	0.88	0.0	-0.19	0.2	-0.16	-0.34	-0.18	-0.16
Pb Ratio	0.0	0.04	1.0	-0.03	-0.23	0.19	0.03	-0.04	-0.05		0.05	0.03	-0.15	0.08	0.02	-0.18	-0.15	-0.16	-0.17	-0.01	-0.06	0.12	-0.05	0.0	-0.05	-0.04
Ev To Sales	0.99	0.28	0.05	-0.59	0.1	-0.14	-0.56	-0.84	-0.01	0.05		-0.56	-0.49	-0.38	-0.55	0.62	-0.7	-0.56	0.08	0.66	-0.31	-0.95	-0.28	-0.18	-0.31	0.89
Free Cash Flow Per Share	-0.56	-0.3	0.03	0.27	0.23	0.74	1.0	0.53	0.04	0.03	-0.56		0.83	0.17	0.99	-0.33	0.5	0.44	-0.08	-0.79	0.29	0.55	0.3	0.23	0.31	-0.53
Roic	-0.47	-0.5	-0.15	0.33	0.38	0.64	0.84	0.58	0.08	-0.15	-0.49	0.83		-0.06	0.82	-0.07	0.65	0.67	0.0	-0.67	0.51	0.42	0.49	0.38	0.53	-0.46
Inventory Turnover	-0.4	-0.05	0.08	-0.09	-0.03	0.05	0.18	0.03	0.32	0.08	-0.38	0.17	-0.06		0.17	-0.92	0.14	-0.23	0.2	-0.12	0.02	0.48	-0.03	0.0	0.02	-0.41
Net Income Per Share	-0.56	-0.24	0.02	0.31	0.2	0.7	1.0	0.53	0.08	0.02	-0.55	0.99	0.82	0.17		-0.32	0.47	0.41	-0.01	-0.82	0.23	0.55	0.24	0.16	0.25	-0.55
Days Of Inventory On Hand	0.63	0.17	-0.18	-0.01	0.08	-0.22	-0.34	-0.26	-0.23	-0.18	0.62	-0.33	-0.07	-0.92	-0.32		-0.27	0.08	-0.03	0.25	-0.17	-0.73	-0.12	-0.14	-0.16	0.57
Payables Turnover	-0.71	-0.68	-0.15	0.35	-0.21	0.26	0.5	0.72	-0.08	-0.15	-0.7	0.5	0.65	0.14	0.47	-0.27		0.87	-0.17	-0.74	0.7	0.59	0.65	0.55	0.71	-0.78
Average Inventory	-0.55	-0.56	-0.16	0.47	-0.12	0.23	0.44	0.77	-0.03	-0.16	-0.56	0.44	0.67	-0.23	0.41	0.08	0.87		-0.13	-0.63	0.57	0.43	0.54	0.4	0.58	-0.6
Capex To Revenue	0.04	0.35	-0.17	0.29	0.06	-0.28	-0.05	0.08	0.88	-0.17	0.08	-0.08	0.0	0.2	-0.01	-0.03	-0.17	-0.13		0.03	-0.37	0.04	-0.34	-0.5	-0.37	-0.07
Cash Per Share	0.72	0.34	-0.01	-0.48	0.29	-0.39	-0.79	-0.68	0.0	-0.01	0.66	-0.79	-0.67	-0.12	-0.82	0.25	-0.74	-0.63	0.03		-0.35	-0.62	-0.33	-0.23	-0.35	0.82
Pocfratio	-0.29	-0.95	-0.06	-0.02	-0.1	0.41	0.28	0.24	-0.19	-0.06	-0.31	0.29	0.51	0.02	0.23	-0.17	0.7	0.57	-0.37	-0.35		0.23	0.92	0.97	1.0	-0.33
Interest Coverage	-0.96	-0.22	0.12	0.49	-0.17	0.22	0.56	0.8	0.2	0.12	-0.95	0.55	0.42	0.48	0.55	-0.73	0.59	0.43	0.04	-0.62	0.23		0.21	0.11	0.23	-0.88
Payout Ratio	-0.26	-0.75	-0.05	-0.05	-0.1	0.43	0.29	0.33	-0.16	-0.05	-0.28	0.3	0.49	-0.03	0.24	-0.12	0.65	0.54	-0.34	-0.33	0.92	0.21		0.88	0.92	-0.3
Capex To Operating Cash Flow	-0.16	-0.91	0.0	-0.15	-0.07	0.41	0.21	0.06	-0.34	0.0	-0.18	0.23	0.38	0.0	0.16	-0.14	0.55	0.4	-0.5	-0.23	0.97	0.11	0.88		0.96	-0.17
Pfcf Ratio	-0.29	-0.95	-0.05	-0.04	-0.09	0.44	0.3	0.25	-0.18	-0.05	-0.31	0.31	0.53	0.02	0.25	-0.16	0.71	0.58	-0.37	-0.35	1.0	0.23	0.92	0.96		-0.33
Days Payables Outstanding	0.94	0.31	-0.04	-0.56	0.41	-0.13	-0.54	-0.81	-0.16	-0.04	0.89	-0.53	-0.46	-0.41	-0.55	0.57	-0.78	-0.6	-0.07	0.82	-0.33	-0.88	-0.3	-0.17	-0.33

Click cells to compare fundamentals

ADMA Biologics Account Relationship Matchups

ADMA Biologics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	7.41	3.98	2.43	4.98	3.92	3.72
Ptb Ratio	8.3	1.9	1.39	5.05	7.49	7.86
Days Sales Outstanding	43.15	114.44	128.86	36.73	38.76	41.63
Book Value Per Share	0.48	1.02	1.01	0.77	0.6	0.9
Free Cash Flow Yield	(0.37)	(0.68)	(0.64)	(0.0956)	0.003772	0.003961
Operating Cash Flow Per Share	(1.4)	(1.18)	(0.81)	(0.3)	0.0393	0.0413
Average Payables	7.5M	10.1M	11.8M	12.8M	11.5M	6.5M
Capex To Depreciation	1.17	3.23	2.46	1.96	0.6	0.57
Pb Ratio	8.3	1.9	1.39	5.05	7.49	7.86
Ev To Sales	9.38	4.97	3.07	5.42	4.27	4.06
Roic	(0.45)	(0.41)	(0.29)	(0.17)	0.0814	0.0855
Inventory Turnover	0.74	0.75	0.64	0.73	0.98	1.36
Net Income Per Share	(1.45)	(1.05)	(1.02)	(0.61)	(0.43)	(0.13)
Days Of Inventory On Hand	490.29	485.56	570.7	501.6	372.83	298.54
Payables Turnover	4.31	5.53	6.42	8.98	10.81	11.35
Research And Ddevelopement To Revenue	0.0799	0.14	0.045	0.0235	0.0128	0.0121
Capex To Revenue	0.13	0.3	0.17	0.0903	0.0193	0.0183
Cash Per Share	0.49	0.65	0.37	0.44	0.23	0.22
Pocfratio	(2.85)	(1.65)	(1.75)	(12.9)	115.04	120.8
Interest Coverage	(4.61)	(5.42)	(4.47)	(2.04)	0.86	0.91
Capex To Operating Cash Flow	(0.0334)	(0.05)	(0.12)	(0.23)	0.57	0.59
Pfcf Ratio	(2.72)	(1.46)	(1.56)	(10.46)	265.09	278.34
Days Payables Outstanding	84.77	65.95	56.87	40.64	33.77	32.08
Income Quality	1.58	1.35	1.57	0.9	(0.31)	(0.3)
Roe	(2.18)	(0.99)	(0.6)	(0.56)	(0.21)	(0.2)
Ev To Operating Cash Flow	(3.61)	(2.06)	(2.21)	(14.04)	125.28	131.54
Pe Ratio	(3.81)	(1.92)	(2.33)	(9.01)	(35.85)	(37.64)
Ev To Free Cash Flow	(3.44)	(1.83)	(1.98)	(11.38)	288.67	303.11
Earnings Yield	(0.26)	(0.52)	(0.43)	(0.11)	(0.0279)	(0.0293)
Intangibles To Total Assets	0.0526	0.0288	0.019	0.013	0.0122	0.0116
Net Debt To E B I T D A	(1.61)	(0.7)	(0.97)	(1.71)	17.59	18.47
Current Ratio	6.12	7.71	6.87	6.89	5.16	3.63
Tangible Book Value Per Share	0.36	0.96	0.97	0.75	0.59	0.85
Receivables Turnover	8.46	3.19	2.83	9.94	9.42	11.42
Graham Number	3.37	4.84	3.71	2.73	1.31	1.24

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:

How To Invest In ADMA

Details

Is ADMA Stock a good investment?

Details

What is ADMA Biologics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

Earnings Share

0.27

Revenue Per Share

1.661

Quarterly Revenue Growth

0.781

Return On Assets

0.1989

The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

ADMA Historical Financial Ratios

About ADMA Financial Ratios Analysis

ADMA Biologics Financial Ratios Chart

Price To Sales Ratio

Operating Cash Flow Per Share

Stock Based Compensation To Revenue

Roic

ADMA Biologics fundamentals Correlations

ADMA Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ADMA Biologics fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Sales	+ 0.99	Price To Sales Ratio
Net Income Per Share	+ 0.99	Free Cash Flow Per Share

Interest Coverage	- 0.96	Price To Sales Ratio
Interest Coverage	- 0.95	Ev To Sales
Pfcf Ratio	- 0.95	Dividend Yield
Pocfratio	- 0.95	Dividend Yield
Days Of Inventory On Hand	- 0.92	Inventory Turnover
Capex To Operating Cash Flow	- 0.91	Dividend Yield